Kainos Medicine, Inc. (KOSDAQ:284620)

South Korea · Delayed Price · Currency is KRW

1,087.00

-105.00 (-8.81%)

At close: Aug 14, 2025

-73.03% (1Y)

Market Cap	35.56B -68.7%
Revenue (ttm)	1.17B +43.0%
Net Income	-6.93B
EPS	-211.89
Shares Out	32.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	883,908
Open	1,200.00
Previous Close	1,192.00
Day's Range	1,069.00 - 1,245.00
52-Week Range	960.00 - 6,000.00
Beta	0.88
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Kainos Medicine

Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2007

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 284620

Full Company Profile

Financial Performance

In 2025, Kainos Medicine's revenue was 1.17 billion, an increase of 98.46% compared to the previous year's 590.37 million. Losses were -7.78 billion, -36.14% less than in 2024.

Financial Statements